×

Business / Stock Market

Astellas Pharma Says Rare Neuromuscular Clinical Trial Participant Passed Away

Published Sep 14 2021 at 6:48 AM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

(ALPMY, ALPMY) said Tuesday that the ASPIRO clinical trial'participant, who'developed a serious adverse event, passed away on September 9 The cause of death is still pending.
The ASPIRO clinical trial had evaluated AT132 in patients with X-linked Myotubular Myopathy.
X-linked Myotubular Myopathy is a serious.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Sep 14, 2021 6:48 AM GMT